Abstract

Iron deficiency is prevalent in chronic heart failure (CHF) patients. Nonetheless, the diagnosis is often overlooked and, often, the treatment is commenced just when overt anemia has ensued. Therefore, a better appreciation of this disease is needed, and all seasoned cardiologists should know how to approach CHF patients with iron deficiency correctly, as mandated by clinical practice guidelines. In this comprehensive review, we describe iron homeostasis, the pathophysiologic changes of iron homeostasis, and the clinical implications of iron deficiency on CHF patients. In addition, we delineate the evolution of clinical trials, ranging from the inception to the ongoing clinical trials of iron deficiency treatment in CHF patients. Iron deficiency contributes to the worse clinical outcome of the patients. Numerous studies have reported the clinical benefit of iron supplementation, particularly in intravenous preparation, in heart failure patients regarding symptoms, functional capacity, and quality of life (QoL) improvement. Therefore, the current guidelines recommend routine screening of iron status in all newly diagnosed heart failure patients. Eventually, intravenous iron replacement is recommended for symptomatic heart failure patients with iron deficiency, irrespective of anemia.

Highlights

  • BackgroundHeart failure is one of the most important cardiovascular diseases owing to its significant impact on mortality, morbidity, hospitalization rates, and quality of life (QoL) [1]

  • We describe iron homeostasis, the pathophysiologic changes of iron homeostasis, and the clinical implications of iron deficiency on chronic heart failure (CHF) patients

  • Numerous studies have reported the clinical benefit of iron supplementation, in intravenous preparation, in heart failure patients regarding symptoms, functional capacity, and quality of life (QoL) improvement

Read more

Summary

Introduction

Heart failure is one of the most important cardiovascular diseases owing to its significant impact on mortality, morbidity, hospitalization rates, and quality of life (QoL) [1]. At the end of the 24-week monitoring, the group with intravenous iron had a significant increase in hemoglobin and serum ferritin levels This increase in iron level is accompanied by clinical improvement in heart failure patients, including improvement in symptoms, improvement in functional capacity (50% in the iron group and 28% in the placebo group; p

FCM 1000 mg before discharge
Study design
Iron in Acute
Conclusions
Disclosures
Katz AM
Findings
13. Neubauer S
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.